FineTech Pharmaceutical develops and manufactures active pharmaceutical ingredients (APIs) with the goal of bypassing process and polymorph patents. The company also offers analytical method development and patent analysis to help bring clients products to market more quickly. FineTechs APIs include Cabergoline, Latanoprost, Travoprost, Bimatoprost, Nabilone, donepezil hydrochloride, aminolevulinic acid hydrochloride, melatonin, and methylbenzethonium chloride. The company specializes in organic processes, including multi-step synthesis, polymorph development, chromatography, and chiral and prostaglandin chemistry. FineTech operates in six facilities on a single campus. The facility is FDA registered and the company abides by cGMP standards. Founded as FineTech Laboratories Ltd in conjunction with the Technion Israel Institute of Technology, FineTech has been acquired by OPKO Health Inc, which is controlled by Teva Pharmaceutical Industries.